In this study, the authors showed that dual targeting of BCR-ABL1 and CD70, synergistically eradicated CML LSCs due to more effective prevention of the Wnt pathway activation and rendering CML LSCs more susceptible to cell killing with anti-CD70 immunotherapy [45]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.